Lv45
636 积分 2023-06-27 加入
Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer
50分钟前
求助中
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
1小时前
已完结
Targeting HER2 in breast cancer with brain metastases: a pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments
1天前
待确认
A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer
2天前
已完结
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
6天前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
7天前
已完结
Anthracycline-induced cardiotoxicity: emerging mechanisms and therapies
8天前
已完结
A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer
9天前
已完结
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
9天前
已完结
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
9天前
已完结
皖公网安备34019202002308
